Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2010

Open Access 01-12-2010 | Research article

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study

Authors: David Price, Anne Robertson, Kevin Bullen, Cynthia Rand, Rob Horne, Heribert Staudinger

Published in: BMC Pulmonary Medicine | Issue 1/2010

Login to get access

Abstract

Background

Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes. This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler (MF-DPI) on treatment adherence compared with a twice-daily administration.

Methods

This was a 12-week open-label study designed to mimic an actual clinical setting in patients ≥12 years old with mild-to-moderate persistent asthma. Patients were randomized to receive MF-DPI 400 μg once-daily in the evening or MF-DPI 200 μg twice-daily. Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses. Self-reports were also used to determine adherence. Health-related quality of life, healthcare resource utilization, and days missed from work or school were also reported.

Results

1233 patients were randomized. The mean adherence rates, as measured by the automatic dose counter, were significantly better (P < 0.001) with MF-DPI 400 μg once-daily in the evening (93.3%) than with MF-DPI 200 μg twice-daily (89.5%). Mean adherence rates based on self-reports were also significantly better (P < 0.001) with MF-DPI 400 μg QD PM (97.2%) than with MF-DPI 200 μg twice-daily (95.3%). Adherence rates were lower in adolescents (12-17 years old). Health-related quality of life improved by 20% in patients using MF-DPI once-daily in the evening and by 14% in patients using MF-DPI twice-daily. Very few (<8%) patients missed work/school.

Conclusion

Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.
This trial was completed prior to the ISMJE requirements for trial registration.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Chmelik F, Doughty A: Objective measurements of compliance in asthma treatment. Ann Allergy. 1994, 73 (6): 527-532.PubMed
4.
Onyirimba F, Apter A, Reisine S, Litt M, McCusker C, Connors M, ZuWallack R: Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence. Ann Allergy Asthma Immunol. 2003, 90 (4): 411-415. 10.1016/S1081-1206(10)61825-X.CrossRefPubMed
5.
Bender B, Milgrom H, Rand C: Nonadherence in asthmatic patients: is there a solution to the problem?. Ann Allergy Asthma Immunol. 1997, 79 (3): 177-185. 10.1016/S1081-1206(10)63001-3.CrossRefPubMed
6.
Bender B, Milgrom H, Apter A: Adherence intervention research: what have we learned and what do we do next?. J Allergy Clin Immunol. 2003, 112 (3): 489-494. 10.1016/S0091-6749(03)01718-4.CrossRefPubMed
7.
Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B: Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000, 343 (5): 332-336. 10.1056/NEJM200008033430504.CrossRefPubMed
8.
Bender BG, Rand C: Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol. 2004, 4 (3): 191-195. 10.1097/00130832-200406000-00009.CrossRefPubMed
9.
Stempel DA, Roberts CS, Stanford RH: Treatment patterns in the months prior to and after asthma-related emergency department visit. Chest. 2004, 126 (1): 75-80. 10.1378/chest.126.1.75.CrossRefPubMed
10.
Guest JF, Davie AM, Ruiz FJ, Greener MJ: Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J. 2005, 14 (2): 88-98. 10.1016/j.pcrj.2005.01.002.CrossRefPubMed
11.
Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001, 23 (8): 1296-1310. 10.1016/S0149-2918(01)80109-0.CrossRefPubMed
12.
Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, Ilersich AL: Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002, 24 (2): 302-316. 10.1016/S0149-2918(02)85026-3.CrossRefPubMed
13.
Osterberg L, Blaschke T: Adherence to medication. N Engl J Med. 2005, 353 (5): 487-497. 10.1056/NEJMra050100.CrossRefPubMed
14.
Nathan RA, Nayak AS, Graft DF, Lawrence M, Picone FJ, Ahmed T, Wolfe J, Vanderwalker ML, Nolop KB, Harrison JE: Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol. 2001, 86 (2): 203-210. 10.1016/S1081-1206(10)62692-0.CrossRefPubMed
15.
Bousquet J, D'Urzo A, Hebert J, Barraza CH, Boulet LP, Suarez-Chacon R, Harnest U, Lundback B, Martinez Morales G, Nieminen MM, et al: Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J. 2000, 16 (5): 808-816. 10.1183/09031936.00.16580800.CrossRefPubMed
16.
O'Connor B, Bonnaud G, Haahtela T, Luna JM, Querfurt H, Wegener T, Lutsky BN: Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol. 2001, 86 (4): 397-404.CrossRefPubMed
17.
Corren J, Berkowitz R, Murray JJ, Prenner B: Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract. 2003, 57 (7): 567-572.PubMed
18.
Wardlaw A, Larivee P, Eller J, Cockcroft DW, Ghaly L, Harris AG: Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol. 2004, 93 (1): 49-55. 10.1016/S1081-1206(10)61446-9.CrossRefPubMed
19.
Bernstein DI, Berkowitz RB, Chervinsky P, Dvorin DJ, Finn AF, Gross GN, Karetzky M, Kemp JP, Laforce C, Lumry W, et al: Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med. 1999, 93 (9): 603-612. 10.1016/S0954-6111(99)90099-9.CrossRefPubMed
20.
Nayak AS, Banov C, Corren J, Feinstein BK, Floreani A, Friedman BF, Goldsobel A, Gottschlich GM, Hannaway PJ, Lampl KL, et al: Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol. 2000, 84 (4): 417-424. 10.1016/S1081-1206(10)62275-2.CrossRefPubMed
21.
Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE: Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol. 2000, 106 (3): 485-492. 10.1067/mai.2000.109431.CrossRefPubMed
22.
Noonan M, Karpel JP, Bensch GW, Ramsdell JW, Webb DR, Nolop KB, Lutsky BN: Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol. 2001, 86 (1): 36-43. 10.1016/S1081-1206(10)62353-8.CrossRefPubMed
23.
Bensch GW, Prenner B, Berkowitz R, Galant S, Ramsdell J, Lutsky B: Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol. 2006, 96 (4): 533-540. 10.1016/S1081-1206(10)63547-8.CrossRefPubMed
24.
Karpel JP, Busse WW, Noonan MJ, Monahan ME, Lutsky B, Staudinger H: Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann Pharmacother. 2005, 39 (12): 1977-1983. 10.1345/aph.1G410.CrossRefPubMed
25.
D'Urzo A, Karpel JP, Busse WW, Boulet LP, Monahan ME, Lutsky B, Staudinger H: Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin. 2005, 21 (8): 1281-1289.CrossRefPubMed
26.
Storms W: Clinical trials: are these your patients?. J Allergy Clin Immunol. 2003, 112 (5 suppl): S107-S111. 10.1016/j.jaci.2003.09.019.CrossRefPubMed
27.
Bayliss MS, Espindle DM, Buchner D, Blaiss MS, Ware JE: A new tool for monitoring asthma outcomes: the ITG Asthma Short Form. Qual Life Res. 2000, 9 (4): 451-466. 10.1023/A:1008939328060.CrossRefPubMed
28.
ZuWallack R, Adelglass J, Clifford DP, Duke SP, Wire PD, Faris M, Harding SM: Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Chest. 2000, 118 (2): 303-312. 10.1378/chest.118.2.303.CrossRefPubMed
29.
Busse W, Raphael GD, Galant S, Kalberg C, Goode-Sellers S, Srebro S, Edwards L, Rickard K: Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol. 2001, 107 (3): 461-468. 10.1067/mai.2001.114657.CrossRefPubMed
30.
Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, Ullman A, Lamm CJ, O'Byrne PM: Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003, 361 (9363): 1071-1076. 10.1016/S0140-6736(03)12891-7.CrossRefPubMed
31.
32.
Rand C, Bilderback A, Schiller K, Edelman JM, Hustad CM, Zeiger RS: Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J Allergy Clin Immunol. 2007, 119 (4): 916-923. 10.1016/j.jaci.2006.12.664.CrossRefPubMed
33.
Horne R, Weinman J: Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychology and Health. 2002, 17 (1): 17-32. 10.1080/08870440290001502.CrossRef
34.
Boulet LP: Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest. 1998, 113 (3): 587-592. 10.1378/chest.113.3.587.CrossRefPubMed
35.
Horne R, Price D, Cleland J, Costa R, Covey D, Gruffydd-Jones K, Haughney J, Henrichsen SH, Kaplan A, Langhammer A, et al: Can asthma control be improved by understanding the patient's perspective?. BMC Pulm Med. 2007, 7: 8-10.1186/1471-2466-7-8.CrossRefPubMedPubMedCentral
Metadata
Title
Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study
Authors
David Price
Anne Robertson
Kevin Bullen
Cynthia Rand
Rob Horne
Heribert Staudinger
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2010
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-10-1

Other articles of this Issue 1/2010

BMC Pulmonary Medicine 1/2010 Go to the issue

Research article

Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV

Research article

Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients

Research article

Prevalence of gastro-oesophageal reflux disease symptoms and reflux-associated respiratory symptoms in asthma

Research article

Mechanical ventilation modulates Toll-like receptor-3-induced lung inflammation via a MyD88-dependent, TLR4-independent pathway: a controlled animal study

Research article

An integrative review of systematic reviews related to the management of breathlessness in respiratory illnesses

Research article

Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits